Article
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
Antiviral research - 1 Aug 2002
Ives J A L, Carr J A, Mendel D B, Tai C Y, Lambkin R, Kelly L, Oxford J S, Hayden F G, Roberts N A
Abstract excerpt
Oseltamivir carboxylate is a potent and specific inhibitor of influenza A and B neuraminidase (NA). Oseltamivir phosphate, the ethyl ester prodrug of oseltamivir carboxylate, is the first orally active NA inhibitor available for the prophylaxis and treatment of influenza A and B. It offers an improvement over amantadine and rimantadine which are active only against influenza A and rapidly generate resistant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.